Markov modelling in healthcare economic evaluations

Chinese Journal of Evidence-Based Medicine

Volumn 7, Issue 10, 2007, Pages 750-756

  Sun, Xin ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN;

ARTICLE; CHRONIC HEPATITIS; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEPATITIS B; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MEDICAL EXPERT; MONTE CARLO METHOD; PROBABILITY; PROGNOSIS; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SEROCONVERSION; STATISTICAL MODEL; TREATMENT OUTCOME; UNCERTAINTY; VISUAL ANALOG SCALE;

EID: 35948976506     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sun X, Orlewska E, Li YP, et al. Methods for economicevaluation of marketed medicines II: Conducting primary economicevaluation. Chinese Journal of Evidence-Based Medicine, 6: 218-223.
2. Karnon J . Alternative decisionmodelling techniques for the evaluation of health care technologies:Markov processes versus discrete event simulation. HealthEcon, 12: 837-848
3. Orlewska E. The Cost-Effectiveness of Alternative Therapeutic Strategies for the Management of ChronicHepatitis B in Poland. Value Health, 5: 405-421.
4. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. John Wiley & Sons, Ltd.
5. Breese JS. Construction of belief and decision networks. Computat Intel, 8: 624-647.
6. Powell C. The Delphi technique: myths and realities. J Adv Nurs, 41: 376-382.
7. Van Steenkiste BC, Jacobs JE, Verheijen NM, et al .A Delphi technique as a method for selecting the content of an electronicpatient record for asthma. International Journal of Medical Informatics, 65: 7-16.
8. Salomon JA, Murray CJL. A multi-method approach to measuring health-state valuations, 13: 281-290.
9. Brazier J, Deverill M, Green C, et al. A review of the use of health states measures in economicevaluation. HealthTechnol Assess. 3(9).
10. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of healthcare technologies: the role of sensitivity analysis. HealthEconomics. 3: 95-104.
11. Briggs HA. Handling Uncertainty in Cost-Effectiveness Models. Pharmacoeconomics, 17: 479-500.
12. Nuijten MJC. Incorporation of Statistical Uncertainty in Health EconomicModelling Studies Using Second-Order Monte Carlo Simulations. Pharmacoeconomics, 22: 759-769.
13. Sonnenberg FA, Roberts MS, Tsevat J, et al. Toward a peer review process for medical decision analysis models. Medical Care, 32: JS52-64.
14. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economicevaluation of pharmaceuticals: Canada[3rd ed]. Ottawa: Canadian Agency for Drugs and Technologies in Health.
15. Weistein MC, O'Brien B, Hornberger J, et al. Principles of Good Practice for Decision AnalyticModeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 6: 9-17.
16. Manca A, Rice N, Sculpher MJ, et al. Assessing general isability by location in trial-based cost-effectiveness analysis: the use of multilevel models. 14: 471-485.
17. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 312: 1443-8.
18. Nuijten MJC, Hardens M. Measuring sensitivity in pharmacoeconomicstudies: an integration of point-sensitivity and range sensitivity. Pharmacoeconomics, 12: 555-564.
19. Heitjan DF, Li H. Bayesian estimation of cost-effectiveness: an importance-sampling approach. HealthEcon, 13: 191-198.
20. Vanness DJ, Kim WR. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. HealthEcon 11: 551-566.
21. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Making 18(2 Suppl): S65-S80.
22. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J 148: 913-917.
23. Fenwick E, Marshall DA, Levy AR, et al. Using and interpreting cost-effectiveness acceptability curves: An example using data from a trial of management strategies for atrial fibrillation. BMC Health Services Research 6:52.
24. Sendi PP, Briggs AH. Affordability and cost-effectiveness: Decision-making on the cost-effectiveness plane. HealthEcon, 10: 675-680.
25. Bala MV, Mauskopf JA. Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts Pharmacoeconomics, 24: 345-54.